Exagen Inc Total Liabilities
Exagen Inc total liabilities. Based on the latest financial reports, Exagen Inc (XGN) has total liabilities worth $39.72 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Exagen Inc (XGN) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Exagen Inc (2012–2025)
Total liabilities of Exagen Inc from 2012 to 2025. This chart illustrates how Exagen Inc's total liabilities have evolved over time, based on quarterly financial data.
Exagen Inc Competitors by Total Liabilities
The table below lists competitors of Exagen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crown Reserve Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CRAC
|
USA | $2.22 Million |
|
GP-Act III Acquisition Corp. Class A Ordinary Share
NASDAQ:GPAT
|
USA | $16.42 Million |
|
Compania Espanola de Viviendas en Alquiler SA
MC:CEV
|
Spain | €187.28 Million |
|
Brainchip Holdings Ltd
AU:BRN
|
Australia | AU$3.46 Million |
|
Aekyung Industrial Co Ltd
KO:018250
|
Korea | ₩82.54 Billion |
|
LIFELINE SPAC I OYJ A EO1
F:0CD
|
Germany | €9.90 Million |
|
Sekerbank TAS
IS:SKBNK
|
Turkey | TL265.57 Billion |
|
Vieworks Co. Ltd
KQ:100120
|
Korea | ₩103.22 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Exagen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Exagen Inc's balance sheet.
Liquidity & Leverage Metrics
Exagen Inc Total Liabilities Ratios Explained
Exagen Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Exagen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Exagen Inc (2012–2025)
The table below shows the annual total liabilities of Exagen Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $40.57 Million | +15.43% |
| 2024-12-31 | $35.15 Million | +2.62% |
| 2023-12-31 | $34.25 Million | -21.73% |
| 2022-12-31 | $43.76 Million | +13.64% |
| 2021-12-31 | $38.51 Million | +5.40% |
| 2020-12-31 | $36.54 Million | +11.90% |
| 2019-12-31 | $32.65 Million | -8.34% |
| 2018-12-31 | $35.62 Million | +42.32% |
| 2017-12-31 | $25.03 Million | -32.01% |
| 2015-12-31 | $36.81 Million | +17.97% |
| 2014-12-31 | $31.20 Million | +95.03% |
| 2013-12-31 | $16.00 Million | +148.29% |
| 2012-12-31 | $6.44 Million | -- |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more